These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 19804996

  • 1. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
    Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM.
    Blood Cells Mol Dis; 2010 Jan 15; 44(1):41-7. PubMed ID: 19804996
    [Abstract] [Full Text] [Related]

  • 2. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
    Canda E, Kose M, Kagnici M, Ucar SK, Sozmen EY, Coker M.
    Blood Cells Mol Dis; 2018 Feb 15; 68():180-184. PubMed ID: 28111116
    [No Abstract] [Full Text] [Related]

  • 3. Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia.
    Goldblatt J, Fletcher JM, McGill J, Szer J, Wilson M.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):107-10. PubMed ID: 20684886
    [Abstract] [Full Text] [Related]

  • 4. [Gaucher's disease and imiglucerase in 2009/2010: what leads to a suddenly enforced prioritisation?].
    Hofstetter K, Raspe H, Stumpf S, Framke S.
    Gesundheitswesen; 2015 Feb 15; 77(2):86-92. PubMed ID: 24671892
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
    Giraldo P, Irún P, Alfonso P, Dalmau J, Fernández-Galán MA, Figueredo A, Hernández-Rivas JM, Julia A, Luño E, Marín-Jimenez F, Martín-Nuñez G, Montserrat JL, de la Serna J, Vidaller A, Villalón L, Pocovi M.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):115-8. PubMed ID: 20934891
    [Abstract] [Full Text] [Related]

  • 6. Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination.
    Capablo JL, Franco R, de Cabezón AS, Alfonso P, Pocovi M, Giraldo P.
    Epilepsia; 2007 Jul 15; 48(7):1406-8. PubMed ID: 17433057
    [Abstract] [Full Text] [Related]

  • 7. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C, Swiader L, Serratrice J.
    J Med Case Rep; 2015 Jun 23; 9():146. PubMed ID: 26100396
    [Abstract] [Full Text] [Related]

  • 8. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M, Barzegar S, Pan L, Shi P, Oommen S, Durant J, Ruiz JA.
    J Immunol Methods; 2011 Oct 28; 373(1-2):45-53. PubMed ID: 21846471
    [Abstract] [Full Text] [Related]

  • 9. Imiglucerase in the treatment of Gaucher disease: a history and perspective.
    Deegan PB, Cox TM.
    Drug Des Devel Ther; 2012 Oct 28; 6():81-106. PubMed ID: 22563238
    [Abstract] [Full Text] [Related]

  • 10. Individualization of long-term enzyme replacement therapy for Gaucher disease.
    Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, International Collaborative Gaucher Group U.S. Regional Coordinators.
    Genet Med; 2005 Feb 28; 7(2):105-10. PubMed ID: 15714077
    [Abstract] [Full Text] [Related]

  • 11. Use of Identical INN "Imiglucerase" for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database.
    Tsang SF, Pandya S, Barakov K, Keutzer J, Lewis G, Ross L, Freisens S.
    Drug Saf; 2022 Feb 28; 45(2):127-136. PubMed ID: 35020177
    [Abstract] [Full Text] [Related]

  • 12. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
    Prescrire Int; 2005 Oct 28; 14(79):168-70. PubMed ID: 16285070
    [Abstract] [Full Text] [Related]

  • 13. Gaucher disease, enzyme replacement therapy, and the Patient Assistance Program.
    Goldwater RS.
    J Intraven Nurs; 1996 Oct 28; 19(2):83-8. PubMed ID: 8852168
    [Abstract] [Full Text] [Related]

  • 14. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.
    Stirnemann J, Rose C, Serratrice C, Dalbies F, Lidove O, Masseau A, Pers YM, Baron C, Belmatoug N.
    Orphanet J Rare Dis; 2015 May 13; 10():62. PubMed ID: 25968608
    [Abstract] [Full Text] [Related]

  • 15. [Therapeutic objectives in Gaucher disease].
    Mistry P, Germain DP.
    Rev Med Interne; 2007 Oct 13; 28 Suppl 2():S171-5. PubMed ID: 18228683
    [Abstract] [Full Text] [Related]

  • 16. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.
    J Bone Miner Res; 2007 Jan 13; 22(1):119-26. PubMed ID: 17032149
    [Abstract] [Full Text] [Related]

  • 17. The long-term international safety experience of imiglucerase therapy for Gaucher disease.
    Starzyk K, Richards S, Yee J, Smith SE, Kingma W.
    Mol Genet Metab; 2007 Feb 13; 90(2):157-63. PubMed ID: 17079176
    [Abstract] [Full Text] [Related]

  • 18. Gaucher disease: unmet treatment needs.
    Mehta A.
    Acta Paediatr; 2008 Apr 13; 97(457):83-7. PubMed ID: 18339195
    [Abstract] [Full Text] [Related]

  • 19. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM.
    Curr Opin Investig Drugs; 2010 Apr 13; 11(4):472-8. PubMed ID: 20336596
    [Abstract] [Full Text] [Related]

  • 20. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS, DiRocco M, Kaplan P, Mehta A, Pastores GM, Smith SE, Puga AC, Lemay RM, Weinreb NJ.
    Mol Genet Metab; 2009 Apr 13; 96(4):164-70. PubMed ID: 19195916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.